Smart science to improve lives™


Formed as a joint venture company in 1977, Croda Mexico is today wholly owned by Croda. We are located in Ciudad de Mexico (CDMX), the country’s main economic, financial, business and cultural centre. In addition to sales, marketing and customer service, our offices also have an applications laboratory supporting customers across Latin America. 

With strong working relationships across the Croda Group the team benefits from many personal and professional development opportunities and enjoys donating working time to take part in Croda 1% Club activities. 
office in mexico

Croda Mexico

Av. Paseo de la Reforma 296, Piso 17, Oficina B
Colonia Juárez, Del. Cuauhtémoc, Mexico City
Mexico D.F., C.P 06600
Tel: +52 55 36405710

Iberchem Mexico S.A. de C.V.

Alfredo Nobel No. 3, 3 y 4
Col. Fraccionamiento Industrial Los Reyes
Estado de México
54073 Tlalnepantla
Tel: +52 55 5565 5450

Our Innovation Centre at global headquarters Cowick Hall

Contact us

Whether you’re a customer, potential partner, job seeker or investor, please use our contact us form for your enquiry.

Croda Formulator at work in labs

Where we operate

Every day our global team, across 37 countries, work together to inspire our customers.

Further reading

Sustainability expert Aris Vrettos joins Croda

The new position will see the sustainability expert challenge Croda to stretch its already industry-leading sustainability ambitions and commitments and support Croda’s business sectors in further...

Read more

Launch of first report on biotechnology opportunities in the personal care market

27 September 2022: The “Biotechnology: personal care market report” is the first in a series from Croda which aim to help other forward-thinking companies leverage the opportunities offered by...

Read more

U.S. Government to support expansion of Croda lipid systems capability

Today we announce a joint investment with the U.S. government to expand our U.S manufacturing capacity for lipid systems used in novel therapeutic drugs, such as mRNA vaccines

Read more

Excellent first half performance driving profit growth

Excellent first half performance driving profit growth

Read more